Press Releases

AV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced data from nonclinical

VistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningham, to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 15, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced the appointment of

VistaGen Therapeutics to Present at 11th Annual Biotech Showcase

SOUTH SAN FRANCISCO, Calif., Dec. 27, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that it will present at

VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101

New Hong Kong patent complements counterpart patents previously issued in China, Europe and the U.S. SOUTH SAN FRANCISCO, Calif., Nov. 29, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central

VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced receiving Notices of

VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today reported financial results

VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study

PH10 demonstrated in Phase 2a study significant antidepressant effects without psychological side effects after only one week of administration SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company

VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics Inc ( NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that Shawn Singh,

VistaGen Therapeutics Appoints Dr. Michael Liebowitz to CNS Clinical and Regulatory Advisory Board in Preparation for Pivotal Phase 3 Development of PH94B as the First Rapid-Acting, On-Demand Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics Inc ( NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced the appointment of

VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain

Designation highlights serious unmet need for new treatment options for patients suffering from neuropathic pain Second FDA Fast Track designation for AV-101 since December 2017 marks another milestone for VistaGen's R&D pipeline SOUTH SAN FRANCISCO, Calif., Oct.